The California Institute for Regenerative Medicine (CIRM) has awarded $6 million to Keck Medicine of USC investigators pioneering a new first-of-its-kind genetic therapy for glioblastoma, a highly aggressive form of brain cancer. The treatment would be the first gene therapy for glioblastoma to use a more precise delivery system that is less likely to harm non-cancerous cells.

The three-year grant, led by USC in collaboration with members of the Zolotukhin Lab at the University of Florida, builds on three advances the team has made towards a novel GBM treatment, with the goal of moving it closer to clinical trials.

Currently, glioblastoma has no known cure and an average five-year survival rate of just 5%.

To read the full story, click here.